StemCell Therapy

Some people believe that it is impossible to ionize water, others believe the product is too good to be true.

It is important to note that the ionization of water can be tested using scientific measuring devices such as pH and ORP meters. According to The Miraculous Properties of Ionized Water, the changes that ionization produceareradical, immediate, and measurable.

Ionized water is the charging of water by creating negative ions (-OH) and positive ions (+OH). They are created through electrolysis and then the ions are separated through a membrane, so the water is negatively charged.

There has been a considerable amount of research conducted on the effects of ionized water. Most of the research has been conducted by the Japanese. All of the research has arrived at the same conclusion: ionized water benefits everything it comes in contact with as long as its used correctly. There is hard scientific evidence to back up this claim.

There are strong detoxing effects of ionized water, which proves it is not like any other water consumed. These detoxing effects are due to the small water-molecule cluster size. Water-molecule cluster size is measured using a Nuclear Magnetic Resonance device. The change in the surface tension of ionized water can also be determined. It is measured in dynes. The lower the surface tension, the smaller the water-molecule clusters.

Water is the most essential element needed by the body; therefore, health begins with water. It is impossible to be truly healthy without being properly hydrated.

When babies are born, their bones are mostly water. They are more pliable at birth than at any other time in their lives. As people grow older, the bones dry out and become brittle. The body takes the calcium from the bones to distribute it to other parts of the body that need it more.

By the age of 65, the average person is 50-70 percent dehydrated.This is whythe elderly are riddled with disease and constipation.

Bone marrow is critical to the immune system because it contains T-cells, B-cells and other cells that together form the immune system. White blood cells produce antibodies that have a multitude of other immune functions. Red blood cells carry oxygen, produce stem cells and blood platelets that allow the blood to clot.

Stem cells are primitive cells that continue to divide into infinity and form any other cell the body needs. These cells are birthed out of bone marrow, which makes hydration critical to the body. It is imperative to keep bone marrow hydrated, cleansed, and rejuvenated for great health and longevity.

Every single organ in the body requires water to properly function to its full capacity. The body is 69 percent water. The brain is 85 percent water, bones 35 percent water, blood 83 percent water, and the liveris90 percent water.

When the body is dehydrated, it puts ones health in immediate danger. Each day people should drink half their body weight in ounces. However, The Miraculous Properties of Ionized Water recommends people drink much more than half their body weight in water because that amount of water is lost through basic functions of the human body, such as urinating, sweating, breathing, and defecating.

The National Research Council guidelines suggest that the body requires one milliliter of water for every calorie of food consumed, which tends to be half of ones body weight. For example, if one weighs 200 pounds, they should drink 100 ounces of water. According to the official report from the National Research Council states that most of this quantity is contained in prepared foods. This implies that people will get the water they need from the foods they eat and drinking water is not necessary.

These types of misconceptions lead people to believe that water is a choice, not a necessity. Digestion is dehydrating and requires a large amount of water from the bodys reserves. Additionally, the typical American diet consists of dry, cooked and processed foods. Raw foods contain significant amounts of water and are better for ones diet.

There are some who believe that water consumed in raw foods is enough to hydrate the body. This is not true. Even if one could eat enough raw foods to hydrate the body, water would still be required to flush the digestive tract between meals. This is one of the healthiest things one can do. None of the bodys processes will function to capacity if the body is not well hydrated.

By Jeanette Vietti

Source:

The Miraculous Properties of Ionized Water

Image Courtesy of Rubbermaid Products Flickr Page Creative Commons License

body, spot

More here:
Why Proper Hydration Is Necessary for the Body to Function - Guardian Liberty Voice

Aspen Neuroscience, a new biotech company, has raised $6.5 million to develop cell therapies for Parkinsons disease using patients own cells.

The company was co-founded by renowned stem cell scientists Jeanne F. Loring, PhD, and Andres Bratt-Leal, PhD, and initially supported by Summit for Stem Cell, a non-profit organization that provides a variety of services for Parkinsons patients.

Parkinsons hallmark motor symptomsinclude tremor, slowness of movement (bradykinesia), stiffness (rigidity), uncontrollable movements (dyskinesia), and poor balance.

As the disease progresses, patients typically need to gradually increase their dopaminergic therapeutic dose for maximum benefit. Even after that they might sometimes experience reappearance or worsening of symptoms due to diminishing effects of dopaminergic therapy, known was off periods.

Importantly, dopaminergic therapy is delivered to areas of the brain other than the striatum, a key motor control region severely affected in Parkinsons disease. Because of the therapys off-target behavior, patients also may experience side effects such as hallucinations or cognitive impairment.

Aspen wants to combine its expertise in stem cell biology, genomics and neurology and develop the first autologous (self) stem cell-based therapy for Parkinsons disease.

In this type of cell therapy, a patients own cells (usually skin cells) are reprogrammed back into a stem cell-like state, which allows the development of an unlimited source of almost any type of human cell needed, including dopamine-producing neurons, which are those mainly affected by this disorder.

Because these cells are derived from patients, they do not carry the risk of being rejected once re-implanted, eliminating the need for immunosuppressive complementary therapies, which carry serious side effects such as infections and possibly limiting therapeutic potential.

In theory, replacing lost dopaminergic neurons with new stem cell-derived dopamine-producing ones could potentially ease or reverse motor symptoms associated with the disease.

Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinsons disease, Howard J. Federoff, MD, PhD, Aspens CEO, said in a press release.

We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist, Federoff said.

The companys lead product (ANPD001) is undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinsons disease. Aspen experts also are developing a gene-editing treatment (ANPD002) for familial forms of Parkinsons, starting with the most common genetic variant in the GBAgene, which provides instructions to make the enzyme beta-glucocerebrosidase.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32, according to the press release.

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

The rest is here:
Aspen Neuroscience Receives $6.5M for Parkinson's Stem Cell Therapy - Parkinson's News Today

Liming Wang,1,* Shigao Huang,2,* Shimei Li,1 Ming Li,1 Jun Shi,1 Wen Bai,1 Qianyun Wang,1 Libo Zheng,3 Yongjun Liu3

1Cell Therapy Center, 986 Hospital of Peoples Liberation Army Air Force, Xian, Shaanxi, Peoples Republic of China; 2Cancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, Peoples Republic of China; 3Stem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, Beijing, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Shigao HuangCancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Room 3013, Building N-22, Taipa, Macau, Peoples Republic of ChinaEmail huangshigao2010@aliyun.comYongjun LiuStem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, No. 35, Jinghai 3 Road Economic-Technological Development Area, Beijing, Peoples Republic of ChinaEmail andyliuliu2001@aliyun.com

Background: The traditional anti-inflammation disease-modifying anti-rheumatic drugs (DMARDs) have limited therapeutic effects in rheumatoid arthritis (RA) patients. We previously reported the safety and efficacy of umbilical cord mesenchymal stem cell (UC-MSC) treatment in RA patients that were observed for up to 8 months after UC-MSC infusion. The aim of this study is to assess the long-term efficacy and safety of UC-MSC along with DMARDs for the treatment of RA.Methods: 64 RA patients aged 1864 years were recruited in the study. During the treatment, patients were treated with 40 mL UC-MSC suspension product (2 107 cells/20 mL) via intravenous injection immediately after the infusion of 100 mL saline. The serological markers tests were used to assess safety and the 28-joint disease activity score (DAS28) and the Health Assessment Questionnaire (HAQ) to assess efficacy.Results: 1 year and 3 years after UC-MSC cells treatment, the blood routine, liver and kidney function and immunoglobulin examination showed no abnormalities, which were all in the normal range. The ESR, CRP, RF of 1 year and 3 years after treatment and anti-CCP of 3 years after treatment were detected to be lower than that of pretreatment, which showed significant change (P < 0.05). Health index (HAQ) and joint function index (DAS28) decreased 1 year and 3 years after treatment than before treatment (P < 0.05).Conclusion: UC-MSC cells plus DMARDs therapy can be a safe, effective and feasible therapeutic option for RA patients.

Keywords: rheumatoid arthritis, umbilical cord mesenchymal stem cell, cell therapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Visit link:
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy fo | DDDT - Dove Medical Press

Stem Cell Therapy Market Overview:

The report titled Stem Cell Therapy Market is one of the most comprehensive and important additions to Verified Market Research archive of market research studies. It offers detailed research and analysis of key aspects of the Stem Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Stem Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the Stem Cell Therapy market is carefully analyzed and researched about by the market analysts.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

The report includes detailed analysis of the vendor landscape and thorough company profiling of leading players of the Stem Cell Therapy market.The researchers have considered almost all important parameters for company profiling, including market share, recent development, gross margin, future development plans, product portfolio, production, and revenue.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=TFR&utm_medium=002

Leading players covered in the Stem Cell Therapy market report:

Insight into Competitive Landscape :

Market players need to have a complete picture of the competitive landscape of the Stem Cell Therapy market as it forms an essential tool for them to plan their future strategies accordingly. The report puts forth the key sustainability strategies taken up by the companies and the impact they are likely to have on the Stem Cell Therapy market competition. The report helps the competitors to capitalize on opportunities in the Stem Cell Therapy market and cope up with the existing competition. This will eventually help them to make sound business decisions and generate maximum revenue.

Market Segment Analysis :

The report offers a comprehensive study of product type and application segments of the Stem Cell Therapy market. The segmental analysis provided in the report is based on significant factors such as market share, market size, consumption, production, and growth rate of the market segments studied.Readers of the report are also provided with exhaustive geographical analysis to provide clear understanding of the regional growth of the Stem Cell Therapy market. Developed as well as developing regional markets for Stem Cell Therapy have been deeply studied to help market players identify profit-making opportunities in different regions and countries.

North America (United States, Canada and Mexico)

Asia Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines and Vietnam)

Middle East and Africa (Turkey, GCC Countries, Egypt and South Africa)

South America (Brazil and others)

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=TFR&utm_medium=002

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=TFR&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Read the original here:
Stem Cell Therapy Market Growth Rate by 2026 Top Key Vendors, Trend, Segmentation, Drivers, Challenges and Forecast - Testifyandrecap

Here we are at the end of yet another year, a year that definitely went by faster than the year before or for that matter the year before that. And as ever at this time of year tis the season for casting ahead and divining what the future holds, delivering lists of top 10s and predictions of what will be hot and what will not.

In some fields, the resultant list will look very much like something delivered by the toss of a coin, but in the science and research areas it is pretty certain what will land in the top two or three subjects.

Number one has got to be climate and the impact of global warming. There is no other area that can match it for the variety and depth of research activity being applied to a whole range of climate-related subjects. And the hard news stories keep tumbling out of this endeavour, helping to show that global changes are taking place due to the alterations in climate that we as humans have set in motion.

One peer-reviewed study about the increasingly rapid loss of ice mass over Greenland was published less than a fortnight before Christmas. It showed that the biggest block of land ice in the northern hemisphere was melting away much faster than expected, seven times faster the study suggests.

Published in the journal Nature, it said the island lost 33 billion tonnes of ice on average during the last decade of the 20th century but the average annual ice loss for the most recent 10 years now stands at 254 billion tonnes of ice a year.

This is just one story and one research area, but climate-related studies arise in many fields from alteration of ocean currents to changed rainfall patterns and from species loss to poor air quality. It is also a subject area that affects us all given the potential of coastal flooding, crop losses and human migration to name but a few possible future impacts.

The impacts for humanity are also there in research into new ways to alter our genetic blueprints. The key to unlocking the potential to overcome gene-based diseases relates CRISPR CAS9, our current best technology for getting into the genome and then adding, deleting or altering individual genes.

It has the potential to reverse disease states by correcting unwanted mutations. It is being used in labs around the world as scientists seek to fully understand the method and apply it to alter genes. It is a powerful research tool, for example to create a mouse model that imitates a human disease state and then developing and testing drugs that might be used in humans. It also allows the researcher to look for any unwanted downstream effects arising from genetic alterations.

There are so many scientists using the CRISPR tools that news reports and discoveries will certainly follow. Yet most research scientists are concerned about the lack of controls or limits on what kind of genetic experiments that might be conducted on the human genome. Too little is known about unexpected problems if a number of genes are altered to eliminate a genetic disorder.

There is also the issue of genetic alteration of the germline, the genetic material that moves across to the next generation. There is currently an international block on germline alterations but that has not stopped at least one researcher who went ahead and created the worlds first two genetically modified humans. Breakthroughs will be delivered all through 2020 it is probably safe to say.

What might come third in this short list is up for grabs, and what might produce the next big scientific discovery could come from any direction. For that reason this report becomes a wish list relevant to Irish research and scientific endeavour related to our engagement with important international research bodies.

One of the most important decisions in this regard brings us closer to membership of Cern, Europes premier nuclear research body. A Dil committee studied the research and commercial potential arising from membership and called on the Government to join Cern as quickly as possible.

Cerns huge atom smasher confirmed the existence of the Higgs Boson, an international effort that involved many countries. Ireland could become more involved in this kind of research if it were a member. The Government has already taken the leap and announced our membership of the European Southern Observatory.

Our astronomers and physicists can now get access to some of the worlds largest telescopes based in Chile. The ESO is also a mill for discoveries and this membership gives us the potential to become international players in this field. And in more familiar territory, the Government has renewed its commitment to invest 100 million in the European Space Agency between now and 2024, a decision that ensures Ireland can bid for commercial contracts and researchers can participate in ESA activities. Our investment pays for itself given Irish companies can share in contracts.

All of the research areas mentioned here show how important it is to internationalise Irelands involvement in science. By doing this, we give more opportunities to promising young Irish scientists and help build a strong international reputation for research. Certainly that is not too much to ask for this Christmas.

Originally posted here:
Another year of climate change, genetics and Irish scientific ambition - The Irish Times

Biodiversity the variation in all living organisms is one of Africas richest assets. As a result, its genetic material is coveted by scientists, biotechnology companies and research institutes globally. For decades, there has been a flow of data and biosamples from the African continent to the global north. This has often been in the absence of legitimate participant consent, community engagement or data or material transfer agreements.

Biopiracy the act of directly or indirectly taking undue advantage of research participants and communities in global health research has a long and contentious history in Africa. A recent case occurred during the West African Ebola outbreak between 2014 and 2016 when thousands of biological specimens left the continent without consent. Very often there is minimal benefit sharing.

The issue has been in the news again in South Africa. Accusations have been levelled against the Wellcome Sanger Institute in the UK for allegedly attempting to commercialise data obtained from various African universities. This has reignited questions around models of consent in research, donor rights, biopiracy and genomic sovereignty.

The latest revelations show that legislation as well as academic research governance bodies have failed to adequately safeguard the rights of vulnerable participants in genomics research.

One missing piece of the puzzle is the limited empirical data on the views of people whose biosamples are taken in the name of research. This would include issues of ownership, future use, export, benefit-sharing and commercialisation.

In 2011 and 2012 we surveyed participants to better understand their views. We recruited participants who had experience with research, the consent process and use of biological samples. They were engaged in studies at academic research units attached to public hospitals and private research centres.

Our findings remain relevant today as many of the issues raised by the people we spoke to have still not been addressed.

Our study was conducted over a 10 month period from September 2011 to June 2012. We sampled 200 participants in the Western Cape and Gauteng provinces in South Africa. Participants who had already consented to use of their blood for research were asked several questions including the following: how they felt about their samples being stored for future use and about them being sent abroad to foreign countries, as well as the possibility of future commercialisation.

Most participants were supportive of research. But many expressed concerns about export of their blood samples and data out of South Africa.

For their part, researchers viewed the biosamples as donations. But participants believed they had ownership rights and were keen on benefit sharing. Almost half of the participants were not in favour of broad consent delegated to a research ethics committee. Their preference was to be contacted again for consent in the future.

The legitimacy of using broad consent models for genomic research and biobanking occupies a contested space among bioethicists and researchers globally. Broad consent allows researchers to use biosamples and data indefinitely for future research.

Usually, with broad consent, future research must be approved by a Research Ethics Committee (a diverse group of experts from different research, medical, legal and ethics disciplines) and it is then not necessary to contact donors and ask for their permission to conduct research with their samples or data again.

But this type of consent is particularly contentious in resource depleted countries. This is because research participants often dont understand the complex scientific jargon used in consent documents or processes, especially where use of their samples or data in the future is concerned. This includes commercialisation.

Strong privacy protection legislation and other similar laws require specific consent. This means that individual participants need to consent to use of their data in a specific project or disease category. This makes it challenging to understand how broad consent (delegated to a research ethics committee) for unspecified future use can be legally obtained in research.

This is particularly concerning where future commercialisation may be included in broad consent models without being explicitly discussed with participants. The language used to explain commercialisation is often vague and not fully comprehensible by vulnerable populations.

South Africa also has protocols in place. For example, clear, explicit, voluntary informed consent is required for all use of data and samples belonging to research participants. If data or samples are to be transferred to other researchers in South Africa or abroad, participants ought to be aware of this and can then consent or decline. However, this is not always what happens.

In addition, if data is to be shared with another institution, a data transfer agreement or material transfer agreement must be signed prior to the transfer. This too does not always happen.

South Africa needs to up its game and reform governance around research ethics. This is particularly necessary in the context of international collaborative research. Good governance needs to incorporate transparency, fairness and honesty.

Research ethics committees and researchers need to ensure that data transfer agreements or material transfer agreements are in place prior to sharing of samples or data.

More importantly, community representatives on research ethics committees should be empowered to review consent documents to establish if appropriate language is used to explain commercialisation and data or sample sharing.

A tiered consent model gives participants choice in terms of how their data or samples could be used in the future. This happens when participants choose what they agree to in the consent document. It also allows for specific choices to be voiced on benefit sharing for participants or their respective communities.

In addition, authentic community engagement with co-creation of knowledge production and benefit sharing is essential to ensure equity in global research.

Read more from the original source:
Africa's genetic material is still being misused - The Conversation Africa

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tucatinib, in combination with trastuzumab and capecitabine, for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have been treated with trastuzumab, pertuzumab, and T-DM1. The positive topline results of the pivotal HER2CLIMB clinical trial were announced in October 2019, and additional data were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) on December 11, 2019 and were simultaneously published in the New England Journal of Medicine (NEJM). Tucatinib is an oral, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2.

The FDAs Breakthrough Therapy process is intended to expedite the development and review of promising drug candidates intended for serious or life-threatening conditions. Designation is based upon preliminary clinical evidence of the potential for substantial improvement over existing therapies on one or more clinically significant endpoints.

The addition of tucatinib to the commonly used combination of trastuzumab and capecitabine demonstrated superior activity compared to trastuzumab and capecitabine alone in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with and without brain metastases, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. The decision by the FDA to grant Breakthrough Therapy designation to tucatinib recognizes the urgent need for new medicines that can impact the lives of those with HER2-positive metastatic breast cancer. We intend to submit a New Drug Application to the FDA and an MAA to the EMA by the first quarter 2020, with the goal of making tucatinib available to patients in this setting as soon as possible.

This Breakthrough Therapy designation was based on data from the pivotal HER2CLIMB clinical trial, which compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer. Patients had previously received trastuzumab, pertuzumab and ado-trastuzumab emtansine (T-DM1). Patients had received a median of four prior lines of therapy overall and three in the metastatic setting. Forty-seven percent of the patients enrolled in the trial had brain metastases at the time of enrollment.

Data presented at SABCS and published in NEJM include the primary endpoint of progression-free survival (PFS) as assessed by blinded independent central review (BICR) in the first 480 patients enrolled in the trial. The primary endpoint of PFS showed that the addition of tucatinib was superior to trastuzumab and capecitabine alone, with a 46 percent reduction in the risk of disease progression or death (hazard ratio (HR)=0.54 (95% Confidence Interval (CI): 0.42, 0.71); p<0.00001). The trial met the two key secondary endpoints at interim analysis. The tucatinib arm demonstrated an improvement in overall survival, with a 34 percent reduction in the risk of death (HR=0.66 [95% CI: 0.50, 0.88]; p=0.0048), compared to the control arm. For patients with brain metastases at baseline, the tucatinib arm also demonstrated superior PFS, with a 52 percent reduction in the risk of disease progression or death, compared to the control arm (HR=0.48 [95% CI: 0.34, 0.69]; p<0.00001).

Tucatinib in combination with trastuzumab and capecitabine was generally well tolerated. The most common adverse events occurring in more than 20 percent of patients in the tucatinib arm vs. the control arm included diarrhea, palmar-plantar erythrodysaesthesia syndrome (PPE), nausea, fatigue, and vomiting. Discontinuation of tucatinib and placebo due to adverse events was 5.7 percent in the tucatinib arm and 3.0 percent in the control arm. Greater than or equal to Grade 3 diarrhea was seen in 12.9 percent of the patients in the tucatinib arm vs. 8.6 percent in the control arm. Antidiarrheal prophylaxis was not required per protocol. Antidiarrheals were used in less than half of all cycles where diarrhea was reported. In both treatment arms, when used, the duration of antidiarrheal treatment was short (median of 3 days/cycle). Greater than or equal to Grade 3 aspartate aminotransferase (AST) was seen in 4.5 percent of the patients in the tucatinib arm vs. 0.5 percent in the control arm, and alanine aminotransferase (ALT) elevation in 5.4 percent vs. 0.5 percent, respectively. Discontinuations due to liver transaminase elevations were infrequent in both arms (ALT: 1.0 vs. 0.5 percent; AST: 0.7 vs. 0.5 percent).

About HER2-Positive Breast Cancer

Patients with HER2-positive breast cancer have tumors with high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the aggressive spread of cancer cells. An estimated 271,270 new cases of invasive breast cancer will be diagnosed in the U.S. in 2019.1 Between 15 and 20 percent of breast cancer cases worldwide are HER2-positive.2 Historically, HER2-positive breast cancer tends to be more aggressive and more likely to recur than HER2-negative breast cancer.2, 3, 4 In patients with metastatic breast cancer, the most common site of first metastasis is in bone, followed by lung, brain, and liver.5, 6 Up to 50 percent of metastatic HER2-positive breast cancer patients develop brain metastases over time.2, 7 Despite recent treatment advances, there is still a significant need for new therapies that can impact metastatic disease, especially brain metastases. There are currently no approved therapies demonstrating progression-free survival or overall survival benefit for the treatment of patients with HER2-positive metastatic breast cancer after progression on T-DM1.8, 9, 10

About HER2CLIMB

HER2CLIMB is a multinational randomized (2:1), double-blind, placebo-controlled, active comparator, pivotal clinical trial comparing tucatinib in combination with trastuzumab and capecitabine compared with trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer who were previously treated with trastuzumab, pertuzumab and T-DM1. The primary endpoint of the trial was PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by blinded independent central review (BICR) in the first 480 patients enrolled in the trial. HER2CLIMB enrolled a total of 612 patients to support the analyses of key secondary endpoints, including overall survival, PFS per BICR in patients with brain metastases at baseline and confirmed objective response rate. Safety data were evaluated throughout the study.

About Tucatinib

Tucatinib is an investigational, orally bioavailable, potent tyrosine kinase inhibitor that is highly selective for HER2 without significant inhibition of EGFR. Inhibition of EGFR has been associated with significant toxicities, including skin rash and diarrhea. Tucatinib has shown activity as a single agent and in combination with both chemotherapy and other HER2 targeted agents such as trastuzumab.1,2 Studies of tucatinib in these combinations have shown activity both systemically and in brain metastases. HER2 is a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal and gastric cancers. HER2 mediates cell growth, differentiation and survival. Tucatinib has been granted orphan drug designation by the FDA for the treatment of breast cancer patients with brain metastases.

In addition to HER2CLIMB, tucatinib is being evaluated in a randomized, double-blind, placebo-controlled, multi-center phase 3 trial of tucatinib in combination with T-DM1 compared to T-DM1 alone, in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, who have had prior treatment with a taxane and trastuzumab. The primary endpoint is progression-free survival per RECIST criteria. Secondary endpoints include overall survival, objective response rate and duration of response. The trial is being conducted in North America and is expected to enroll approximately 460 patients. More information about the phase 3 trial, including enrolling centers, is available at http://www.clinicaltrials.gov.

Tucatinib is also being evaluated in a multi-center, open-label, single-arm phase 2 clinical trial known as MOUNTAINEER, which is evaluating tucatinib in combination with trastuzumab in patients with HER2-positive, RAS wildtype metastatic or unresectable colorectal cancer. The primary endpoint of the trial is objective response rate by RECIST criteria. Progression-free survival, duration of response, overall survival and safety and tolerability of the combination regimen are secondary objectives. Results for 26 patients were evaluated in an analysis and presented at the European Society for Medical Oncology (ESMO) 2019 Congress. Enrollment is ongoing. More information about the MOUNTAINEER trial, including enrolling centers, is available at http://www.clinicaltrials.gov.

About Seattle Genetics

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has a late-stage pipeline including enfortumab vedotin for metastatic urothelial cancer, currently being reviewed for approval by the FDA, and tisotumab vedotin in clinical trials for metastatic cervical cancer, which utilize our proprietary ADC technology. In addition, tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. We are also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of tucatinib, including its possible efficacy, safety and therapeutic uses; anticipated development activities including ongoing and future clinical trials; and intended regulatory actions, including the plan to submit an NDA to the FDA and a MAA to the EMA by the first quarter of 2020. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the possibility of disappointing results in ongoing or future clinical trials despite earlier promising clinical results, the possibility of delays in the submission of an NDA to the FDA and a MAA to the EMA, the possibility that data from the HER2CLIMB trial may not be sufficient to support approval of tucatinib, the possibility of adverse regulatory action. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

References:

1. American Cancer Society, Cancer Facts and Figures 2018-2019.

2. Loibl S, Gianni L (2017). HER2-positive breast cancer. The Lancet 389(10087): 2415-29.

3. Slamon D, Clark G, Wong S, et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-82.

4. American Cancer Society (ACS) (2018). Breast cancer HER2 status. Accessed: December 10, 2018.

5. Kennecke H, Yerushalmi R, Woods R, et al. (2010). Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology 28(20): 3271-7.

6. Berman AT, Thukral AD, Hwang W-T, et al. (2013). Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation Treatment. Clinical Breast Cancer 13(2): 88-94.

7. Duchnowska R, Loibl S, Jassem J (2018). Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treatment Reviews 67: 71-7.

8. Verma S, Miles D, Gianni L, et al. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine 367(19): 1783-91.

9. Geyer CE, Forster J, Lindquist D, et al. (2006). Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine 355(26): 2733-43.

10. Blackwell KL, Burstein HJ, Storniolo AM, et al. (2012). Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study. Journal of Clinical Oncology 30(21): 2585-92.

Read this article:
Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast...

Diversity starts at the gene level

Natural killer (NK) cells are immune cells with potent antiviral and antitumor activities. These cells express several germline-encoded inhibitory receptors (KIRs) that prevent NK cells from killing healthy cells but enable the targeting of infected and transformed cells. Using various imaging techniques and functional assays, Kennedy et al. investigated the effects of genetic diversity in KIR-encoding genes on receptor organization and activity. They found that KIRs encoded by distinct genes were present at varying abundances and in clusters of varying sizes, which led to differences in downstream signaling that affected NK cell function. Together, these data suggest that genetic diversity in KIR-encoding genes affects receptor organization, signaling, and functional outcomes.

Genetic diversity in human natural killer (NK) cell receptors is linked to resistance and susceptibility to many diseases. Here, we tested the effect of this diversity on the nanoscale organization of killer cell immunoglobulin-like receptors (KIRs). Using superresolution microscopy, we found that inhibitory KIRs encoded by different genes and alleles were organized differently at the surface of primary human NK cells. KIRs that were found at low abundance assembled into smaller clusters than those formed by KIRs that were more highly abundant, and at low abundance, there was a greater proportion of KIRs in clusters. Upon receptor triggering, a structured interface called the immune synapse assembles, which facilitates signal integration and controls NK cell responses. Here, triggering of low-abundance receptors resulted in less phosphorylation of the downstream phosphatase SHP-1 but more phosphorylation of the adaptor protein Crk than did triggering of high-abundance receptors. In cells with greater KIR abundance, SHP-1 dephosphorylated Crk, which potentiated NK cell spreading during activation. Thus, genetic variation modulates both the abundance and nanoscale organization of inhibitory KIRs. That is, as well as the number of receptors at the cell surface varying with genotype, the way in which these receptors are organized in the membrane also varies. Essentially, a change in the average surface abundance of a protein at the cell surface is a coarse descriptor entwined with changes in local nanoscale clustering. Together, our data indicate that genetic diversity in inhibitory KIRs affects membrane-proximal signaling and, unexpectedly, the formation of activating immune synapses.

Read the original post:
Genetic diversity affects the nanoscale membrane organization and signaling of natural killer cell receptors - Science

Over the past few years most Americans have been more and more curious about their family trees thanks to kits like 23 and Me and Ancestry.com. But did you know your DNA could be used to solve cold cases, convict people whove committed violent crimes, and even exonerate the wrongfully accused?One local genealogist explains why this seeming harmless gift could unlock a world of answered questions for law enforcement.Closure, is the driving force behind genetic genealogists Shera LaPoint.To be able to give that gift to some one has changed my life. Its the most rewarding thing Ive ever done.

Throughout the years she has closed dozens of cold cases thanks familial DNA but the popularity of DNA testing groups like 23 and Me, have a lesser known option that can be beneficial to law enforcement.

As a tester you have a right to decide what information you want to put out there and who its shared with.

Users can also opt into sharing their DNA with officers helping them in several ways, thanks to new technology.

By uploading your DNA you never know who you will be actually helping. We can take these criminals off the streets, we can exonerate innocent people, we can identify John and Jane Does, and also the fallen military who are unnamed, said LaPoint.They can use my DNA or someone I manage that has agreed to opt in, to help capture a dangerous individuals, then I really dont have a problem, says Mark Richard.

Mark Richard, supports opting into sharing DNA with law enforcement because he says it can close dark chapters in peoples lives.

Richard adds, sometimes these are unsolved crimes where families can not get closure. People dont know what happened from an incident you know someone got murdered or raped and people never know who did it. Then these cases go cold because they didnt have the DNA back then so this is giving families an opportunity for closure.Then you give a DNA kit as a Christmas gift, think about going the extra mile and giving a little bit extra by uploading your DNA. Opting into law enforcement use, and lets make a difference in this world, said LaPoint.Aside from working on cold cases, Shera also uses genetic geology to connect adoptees with their parents . For more information about Shera and all her works, click here.

The rest is here:
Genetic Genealogy Helping Law Enforcement Close Cold Cases and More - News15 | Lafayette, LA - FOX 15

A trip to the theater, museum or art gallery could help you live longer. And the more often you get that culture fix the better, a new study suggests.

Researchers from University College London (UCL) found that people who engaged in the arts more frequently -- every few months or more -- had a 31% lower risk of dying early when compared to those who didn't. Even going to the theater or museum once or twice a year was linked with a 14% lower risk.

They looked at data given by more than 6,000 adults in England age 50 years and older, who were taking part in a wider study on aging.

How often an individual engaged in art activities, which also included exhibitions, concerts and opera but not cinema, was measured at the start of the study in 2004 to 2005. Participants were then followed up for an average of 12 years, during which time deaths were recorded using data from the UK's National Health Service (NHS.)

Why?

The study looked at a range of economic, health and social factors to try and explain why there is a link between "arts engagement" and living longer, although as an observational study it can't establish cause. Part of the reason, the study said, comes down to social and economic differences among those who go and don't go to museums, exhibitions and art galleries.

Wealth, they found, explained about 9% of the association. Cognitive differences, social and civic engagement, mental health, mobility and disability and deprivation also played a role. Things like free time and occupational status made no material difference, said Fancourt.

"Part of the association is attributable to differences in socioeconomic status among those who do and do not engage in the arts, which aligns with research that suggests engagement in cultural activities is socially patterned," the study said.

However, said Fancourt, "over half the association is independent of all the factors we identified that could explain the link."

She said that engaging with the arts can act as a buffer against stress and build creativity that allows people to adapt to changing circumstances. It also helps people build social capital -- accessing emotional support and information that helps people age more successfully.

"We also thought that a greater sense of purpose could play a role," she said. "If this (study) is added to the larger body of evidence, we are getting an increasingly rich picture on how arts can benefit health and it's not about one single outcome. It can have wide ranging benefits and support healthier lives lived longer."

How do you fall in love with art?

"Clinicians who read the paper might recognize the value of the arts, but will also wonder how engagement with culture and the arts could influence longevity," the editorial said.

"There is already much published work about the positive neurophysiological changes induced by activities, including the arts, which enable 'deep play' or 'flow.' However, as the authors note, further research is needed into the possible mechanisms that link cultural engagement with longer life."

Originally posted here:
Visit museums or art galleries and you may live longer, new research suggests - CNN

Among the different modes of freight transport, the trucking industry is possibly the only segment that remains localized and bound to specific regions, unlike the air or maritime sectors that are fundamentally more global.

However nucleated the trucking ecosystems might come across, they share certain traits and woes that are strikingly similar across geographies like excessive fragmentation, lack of visibility and transparency, and general indifference to technology.

Fragmentation creates an environment in which the adoption of common standards or practices is extremely arduous, furthering the issue of digitalization percolation as it requires stakeholders across the horizon to come together and adopt technology en masse.

"Another primary issue with fragmentation is that it leads to massive amounts of siloed data," said Lyall Cresswell, the CEO of Transport Exchange Group, a U.K.-based freight logistics company providing real-time decision-making solutions for businesses. "This is where we come in, democratizing that data and putting it across in a commonly accepted standard format for businesses to consume."

Cresswell spoke of how small- and mid-sized companies in the trucking landscape are often caught in a "deer in the headlights" situation, where they struggle to adopt technology that could help them future-proof their businesses from disruption both from an operational and financial perspective.

"With digitalization initiatives getting more mature over the last couple of years, it is important for businesses to not hold back and look at making decisions. They aren't necessarily making long-term decisions, as the technology might change. But it is critical to move in the direction towards change, as if they remain stagnant, the industry is just going to pass them by," said Cresswell.

In the context of price points on adopting technology into their operations, Cresswell contended that a majority of the solutions are available at a cost that isn't unreasonable. This is due to the technology maturing over the years and in part due to the proliferation of startups that lower prices to gain market share in the space.

"Technology is low-cost now as it's all cloud-based today. We do see some high-end systems that companies might need help in setting up, but most of the time, cloud-based technology is something that you can plug and play instantly," said Cresswell. That said, the trucking industry is chock full of traditional family-owned businesses that oftentimes do not grasp the relevance of technology, making it vital for developers to educate them on technology's scope in improving their operations.

Technology aside, it is hard for any company to accurately identify industry trends and future- proof their operations to address potential challenges. For instance, the Amazon effect that has virtually revolutionized the way logistics work today, was not a trend that was anticipated to scale this quickly until it actually arrived at the scene. In the same vein, technological disruption in the delivery sector via drones, last-mile delivery robots, and autonomous driving technology could alter the future of the transport landscape all in quick time.

Though these are trends that businesses have no control over, it serves them well to look at leveraging things under their control like data streams, which can be used to create operational insights like predictive maintenance, dynamic pricing and capacity availability.

"These are the kind of things that, as a small business owner, you'd have them in your head. But if you are a fleet with over 1,000 trucks, you will have to look at using that data, because without that, the information just partially resides in somebody's head," said Cresswell. "Future-proofing is about taking that data beyond traditional reporting and making use of that in an intelligent way to improve operations."

Image Sourced from Pixabay

Read the rest here:
Future Proofing Is Critical To The Longevity Of Trucking Businesses - Benzinga

Top surprising facts about growing older

Cognitive Behavioral Therapy (CBT) have been well known for years, and it is considered one of the best options to treat the mind of people who suffer from an anxiety disorder. As a part of this therapy, the patient interacts with a mental healthcare professional and discusses feelings, emotions, and behaviour.

Thus, the patient and the psychotherapist will work together to expel the negative thought processes. Now, researchers have found that CBT is helpful in increasing longevity among people who suffer from anxiety and other related disorders.

During the study, researchers selected 46 participants who are suffering from a social anxiety disorder. Nine weeks of CBT treatment were given to these participants, and during this time, no psychotropic drugs were given to them. After nine weeks, researchers checked the blood samples of the participants and found that anxiety levels were reduced drastically.

Surprisingly, researchers also noted a spike in telomerase activity in these blood samples. It should be noted that telomeres a structure in the human DNA that is inherently related to the ageing process. As cells divide and we age, telomeres become slightly shorter. Telomerase is an enzyme that slows down this process, and thus it will effectively promote longevity.

"Telomere length and telomerase activity did not change significantly after treatment, but an increase in telomerase over treatment was associated with reduced social anxiety. Also, lower pretreatment telomerase activity predicted subsequent symptom improvement," wrote the researchers in the study report published in the journal Translational Psychiatry.

Even though CBT is widely used as a treatment for anxiety disorder, this additional benefit will surely enhance its popularity in the coming years, and it will encourage more people any kind of disorder to try this therapy. Currently, this form of therapy is being used among 45 percent of people who suffer from anxiety and other mood disorders.

More here:
This new therapy could boost longevity and can treat anxiety - International Business Times, Singapore Edition

The transaction includes a significant proportion of non-UK overseas lives and will protect the Scheme from the risk of rising costs as a result of pensioner and dependent members living longer than expected.

CMS was appointed by the Scheme as legal counsel for this specific project following a competitive tender process and worked closely together with Hymans Robertson, the lead adviser to the Scheme. In a market first, the transaction optimised efficiencies for the Scheme through a combination of the following: allowing the Scheme to have exposure to Hannover Res credit risk; allowing the Scheme to benefit from Zurich retaining a substantive minority share of the longevity risk (in a product known as Enhanced Pass Through); and providing the Scheme the benefits of transacting with a UK regulated insurance company.The CMS team was led by Pensions Partner, James Parker, with assistance from Maria Rodia, Alex Tomlinson and Laura Clarke.Commenting on the transaction, James Parker said: We are delighted to have been able to assist the trustees to significantly reduce the longevity risk in their scheme and improve the security of members benefits. This is one of a series of high-profile transactions on which we have acted as transaction legal counsel this year, underlining CMS market-leading reputation in the pensions de-risking market.This transaction concludes a busy year for the CMS Pensions Team with highlight transactions including acting for Stanhope Pension Trust, trustee of the GEC 1972 Plan, on a 4.7 billion buy-out transaction with Rothesay Life the UKs biggest ever pension transfer deal.

Read the original:
Pensions - Articles - FTSE 100 pension scheme in ground breaking longevity swap - Actuarial Post

There are few tenements still standing in South London the Pullens Estate in Walworth is one of them.

It has a classic design, which was why it was used to represent London in multi-Oscar-winning movie The Kings Speech, set around the Second World War.

Charlie Chaplin lived there months before he set sail to earn his fortune in the movie industry in the USA. And enduring Streatham supermodel Naomi Campbell lived there, too.

Also resident was Frank Bowling, the first black artist to be elected to the Royal Academy in its history. The buildings were saved by squatters in the 1980s.

The tenements and three yards, occupied by small businesses, are among some of the last surviving in London.

They were once a private estate of 684 flats in 12 blocks, owned by the builders, the Pullens family, until taken over by Southwark council in the late 1970s.

They had been built over 30 years from 1870 by James Pullen and Son of 73 Penton Place without planning permission.

The estate originally had 650 flats, surrounding four separate yards of workplaces of which 360 flats and three yards remain.

The yards are unusual originally, each ground or first-floor workshop opened into one of the two flats situated behind it.

Formed in Amelia Street, Crampton Street, Iliffe Street, Penton Place and Peacock Street, the tenements and the workshops are protected by Conservation Area status.

We dont know precisely what businesses were carried on in the very early days, but by the 1970s there were industrial clogmakers for London Fire Brigade; stationers; makers of ships fans; manufacturers of X-ray machinery; hatmakers; brushmakers; bookbinders; printers as well as furniture makers and restorers.

Two brothers, the Lilleycrops, ran Turners Office Furniture, which was furniture restorer to the Inns of Court.

The first block of 16 flats was built in Penton Place without the required consent of the Metropolitan Board of Works.

But Pullen managed to persuade local officials that his work was good, and continued building until 1901 10 years more than he had been granted permission for.

When the philanthropist Charles Booth was surveying London for his poverty map in 1899, he encountered Mr Pullen at work. Booth said: Old Mr Pullen in a top hat and fustian suit was on a scaffolding superintending.

Booth said demand for the well-built flats was high they were occupied before the paper isdry on the walls often by police officers from Whitehall and Lambeth.

The rent was eight shillings for three rooms, kitchen and scullery, plus six pence a week charged for cleaning the stairs and gas. Each had to make a deposit of 24 shillings effectively barring anypoor tenants.

Behind the blocks, around four yards, were 106 workshops and shops at the entrance.

A young Charlie Chaplin lived in one of the Pullens Buildings for nine months in 1907.

Some of the buildings were damaged during German bombing in the Second World War.

A V1 rocket hit Manor Place by the railway on June 27, 1944 at 10.45pm.

Six houses were blown up in Crampton Street and four in Manor Place.

It also damaged a public wash house and stores in Manor Place, a railway bridge, two arches, and 300 houses and buildings in Manor Place and the surrounding streets.

In the 1970s, the council planned to demolish the buildings.

But it was stopped in the 1980s by squatters under the umbrella of the Pullens Squatter Organisation who, with the full support of residents, campaigned and fought successfully to save them.

Their campaign of direct action and solidarity eventually climaxed in barricades which stopped police and bailiffs entering the buildings. Infoshop an anarchist bookshop and volunteer-run, 100 per cent unfunded, DIY social centre is the last remnant of that protest.

New businesses began to move in during the 1980s silversmiths, fine artists, bookbinders, ceramicists and furniture designer-makers.

Many of the remaining 351 flats in the buildings are owned by the council, which spent millions on refurbishment in 2009.

Naomi Campbell lived in Iliffe Street in the 1990s.

Just under 50 per cent of the flats are now in private hands as leaseholds.

Prices have soared, boosted by the regeneration of Elephant and Castle and Victorian design being back in fashion.

In 2007 a Pullens flat in Iliffe Street sold for 305,000. In 2014 in Iliffe Street a property sold for 365,000. In 2015, another on Iliffe Street went for 435,000.

The historic and architectural importance of the buildings has been recognised by their use in several high-profile films, including The Kings Speech.

These days there are still firms like Rob Dixson, ceremonial swordmaker to the Lord Mayor of London; RimmingtonVian, glassware and ceramics designer/decorators supplying various royal palaces, stately homes and the National Gallery Collection among others; and Kevin OBrien, former artist in residence at the National Gallery during his time in Peacock Yard.

Currently, there is a studio for artist Frank Bowling.

There are also lute makers, potters, jewellers, silversmiths, paper conservators, designers, graphic artists, web designers, furniture designers, architects, furniture makers, video and film-makers, photographers, writers and publishers, musical instrument makers and theatre and film costume makers.

Sales of Roger Batchelors book The Pullens Story, 1879-the Present Day go to the New Life Africa International School, Nakuru, Kenya.

Continued here:
South London Memories: Testament to longevity of tenements - London News Online

news, latest-news,

"Do you know what I've just seen?" I excitedly gasped and gibbered, running up to a group of six complete strangers in the sculpture garden of Canberra's Australian National Gallery. It was early one morning last October and I had just seen Jesus, Our Redeemer, striding confidently across the surface of the waters of nearby Lake Burley Griffin, just as in the Bible he walks on the waters of Galilee, amazing his disciples. The strangers seemed inexplicably unmoved. Strangely still and slow-moving I took them to be a group of Tai-Chi practitioners unprepared to let anything interrupt their oriental ritual. "What's WRONG with you people?" I raged at them. "I bring you thrilling news about Jesus' second coming and you just stand there like crash test dummies!" Exasperated I ran up to one of the strangers and shirtfronted him. The lapels of his shirt had a strangely metallic feel. "Excuse me grandad," a sculpture garden security guard intervened, "please don't touch the sculptures." And it emerged that the group of strangers were not Tai-Chi enthusiasts but Rodin's famous bronze Burghers of Calais. My imperfect eyes, awaiting the corrections of cataract surgery had played yet another trick on me. Suspicious now about my earlier vision I went back to the lake shore to check on my Jesus. It turned out that he, far closer to me now and more easily discerned, was in fact just a bearded mortal man. He was not walking on water but only shuffling across the waters standing upright on a hired paddle board. "I'm glad my cataract surgery is happening soon," I confided to an indistinct woman I was fairly sure was my wife after I arrived home from my morning's embarrassing adventures. I've since had cataract surgery, splendidly restoring hawk-eyed accuracy to my vision. It is something to be grateful for and to rejoice over. And yet. Between rejoicings I find myself half-missing some of the delusions, mirages and hallucinations that wonky vision gave me. I'm reminded of James Thurber's amusing memoir The Admiral on the Wheel in which Thurber (already with wonky vision) tells of adventures he suffered/enjoyed after breaking his glasses and having a long wait for new ones. Waiting for his glasses he saw, or seemed to see, wondrous things. "I saw the Cuban flag flying over a national bank, I saw a gay old lady with a grey parasol walk right through the side of a truck, I saw a cat roll across a street in a small striped barrel, I saw bridges rise lazily into the air, like balloons." Thurber enjoyed seeing these sorts of things and came to realise: "With perfect vision, one is inextricably trapped in the workaday world, a prisoner of reality. For the hawk-eyed person life has none of those soft edges which for me blur into fantasy." I strongly identify with Thurber in all this, although overall I am very glad to have had my eyesight corrected since poor eyesight did cause me some embarrassments. There was the time when I put on the first undies I could find in the laundry basket, my wife's, and got very funny looks later that day in the men's locker room at my gym. Then there was that time at my local shops when, not seeing the shopfronts clearly, I went into the bakery, mistaking it for the chemist's and handed the woman behind the counter my doctor's prescription for a well-known medication pertaining to my sexual health. Now I am too embarrassed to go there again; a shame, since its lamingtons are the best in Australia. But so many of my visual mistakes, like dear Thurber's, had a magic about them that I miss now that surgery has put me back into prison with the hawk-eyed. I miss how at the Yarralumla off-leash dog park my dog always seemed to be playing not with mere dogs but with mythical creatures galore, including unicorns and hippogriffs. Once I threw a ball for a bunyip and it, now with a pixie riding on its back, brought it back to me. I miss, now, the flying things (like albatrosses, pterodactyls and airborne superheroes, like Batman) that used to come down to and gather around my garden's birdbath. An art buff, back in perfect eyesight's prison now I miss some of the things I seemed to see in the great paintings reproduced in my coffee-table books. Where, now, is the mystery object (depending on the state of the light in my study either an iPad, a souvenir snowdome of St Basil's Cathedral or a miniature Schnauzer dog) that always seemed to be there in the lap of Whistler's Mother? Today, hawk-eyed now, all I can find in her lap are the frilly cuffs (reminiscent of the frills on the undergarment I once blush-makingly wore to my gym) of her long-sleeved garment where it meets her folded hands. And, now that I see so pragmatically I can no longer find the lamingtons (perhaps bought from my shopping centre's noble bakery) that always seemed to be there on the table in Leonardo da Vinci's painting The Last Supper. Nor, in the same masterpiece, is Judas any longer holding in his right hand what I always believed before my surgery was either a lamington or a mobile phone. Disappointingly hawk-eyed now, I can see it is, predictably, just a bag of coins. Cataract surgery, so magical in every medical way, has taken everyday magic from my every day.

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/fdcx/doc76o44a3o4iw1eym1o6n6.jpg/r0_642_6000_4032_w1200_h678_fmax.jpg

OPINION

December 22 2019 - 4:30AM

"Do you know what I've just seen?" I excitedly gasped and gibbered, running up to a group of six complete strangers in the sculpture garden of Canberra's Australian National Gallery.

It was early one morning last October and I had just seen Jesus, Our Redeemer, striding confidently across the surface of the waters of nearby Lake Burley Griffin, just as in the Bible he walks on the waters of Galilee, amazing his disciples.

Unicorns at Yarralumla's off-leash dog park: where for art thou? Picture: Shutterstock

The strangers seemed inexplicably unmoved. Strangely still and slow-moving I took them to be a group of Tai-Chi practitioners unprepared to let anything interrupt their oriental ritual.

"What's WRONG with you people?" I raged at them.

"I bring you thrilling news about Jesus' second coming and you just stand there like crash test dummies!"

Exasperated I ran up to one of the strangers and shirtfronted him. The lapels of his shirt had a strangely metallic feel.

"Excuse me grandad," a sculpture garden security guard intervened, "please don't touch the sculptures."

And it emerged that the group of strangers were not Tai-Chi enthusiasts but Rodin's famous bronze Burghers of Calais. My imperfect eyes, awaiting the corrections of cataract surgery had played yet another trick on me.

Suspicious now about my earlier vision I went back to the lake shore to check on my Jesus. It turned out that he, far closer to me now and more easily discerned, was in fact just a bearded mortal man. He was not walking on water but only shuffling across the waters standing upright on a hired paddle board.

"I'm glad my cataract surgery is happening soon," I confided to an indistinct woman I was fairly sure was my wife after I arrived home from my morning's embarrassing adventures.

I've since had cataract surgery, splendidly restoring hawk-eyed accuracy to my vision. It is something to be grateful for and to rejoice over. And yet.

Between rejoicings I find myself half-missing some of the delusions, mirages and hallucinations that wonky vision gave me. I'm reminded of James Thurber's amusing memoir The Admiral on the Wheel in which Thurber (already with wonky vision) tells of adventures he suffered/enjoyed after breaking his glasses and having a long wait for new ones.

Waiting for his glasses he saw, or seemed to see, wondrous things.

"I saw the Cuban flag flying over a national bank, I saw a gay old lady with a grey parasol walk right through the side of a truck, I saw a cat roll across a street in a small striped barrel, I saw bridges rise lazily into the air, like balloons."

Thurber enjoyed seeing these sorts of things and came to realise: "With perfect vision, one is inextricably trapped in the workaday world, a prisoner of reality. For the hawk-eyed person life has none of those soft edges which for me blur into fantasy."

I strongly identify with Thurber in all this, although overall I am very glad to have had my eyesight corrected since poor eyesight did cause me some embarrassments.

There was the time when I put on the first undies I could find in the laundry basket, my wife's, and got very funny looks later that day in the men's locker room at my gym.

Then there was that time at my local shops when, not seeing the shopfronts clearly, I went into the bakery, mistaking it for the chemist's and handed the woman behind the counter my doctor's prescription for a well-known medication pertaining to my sexual health. Now I am too embarrassed to go there again; a shame, since its lamingtons are the best in Australia.

But so many of my visual mistakes, like dear Thurber's, had a magic about them that I miss now that surgery has put me back into prison with the hawk-eyed.

Between rejoicings [of successful cataract surgery] I find myself half-missing some of the delusions, mirages and hallucinations that wonky vision gave me.

I miss how at the Yarralumla off-leash dog park my dog always seemed to be playing not with mere dogs but with mythical creatures galore, including unicorns and hippogriffs. Once I threw a ball for a bunyip and it, now with a pixie riding on its back, brought it back to me.

I miss, now, the flying things (like albatrosses, pterodactyls and airborne superheroes, like Batman) that used to come down to and gather around my garden's birdbath.

An art buff, back in perfect eyesight's prison now I miss some of the things I seemed to see in the great paintings reproduced in my coffee-table books.

Where, now, is the mystery object (depending on the state of the light in my study either an iPad, a souvenir snowdome of St Basil's Cathedral or a miniature Schnauzer dog) that always seemed to be there in the lap of Whistler's Mother? Today, hawk-eyed now, all I can find in her lap are the frilly cuffs (reminiscent of the frills on the undergarment I once blush-makingly wore to my gym) of her long-sleeved garment where it meets her folded hands.

And, now that I see so pragmatically I can no longer find the lamingtons (perhaps bought from my shopping centre's noble bakery) that always seemed to be there on the table in Leonardo da Vinci's painting The Last Supper.

Nor, in the same masterpiece, is Judas any longer holding in his right hand what I always believed before my surgery was either a lamington or a mobile phone. Disappointingly hawk-eyed now, I can see it is, predictably, just a bag of coins.

Cataract surgery, so magical in every medical way, has taken everyday magic from my every day.

More here:
Perfect vision sadly a sight for sore eyes - The Canberra Times

From elementary to high school, children in Japan are breaking records for bad eyesight, an education ministry health survey showed Friday.

According to the survey results, children with uncorrected vision of less than 1.0 on the Japanese acuity scale account for 34.6 percent of elementary school students, 57.5 percent of junior high school students and 67.6 percent of high school students all record highs.

A score of 1.0 is equivalent to 20/20 vision.

Looking at smartphone screens at close distances and reading books may be having some effects on childrens eyesight, the ministry said.

The preliminary figures came from samples collected from the results of medical checkups nationwide for children between 5 and 17 from April to June. A more detailed investigation covering several thousand students will be conducted for the first time in fiscal 2020.

The fiscal 2019 survey also found record high ratios of nasal or paranasal sinus conditions, such as allergic rhinitis, in 12.1 percent of junior high students and 9.9 percent of high school students.

The share of high schoolers with ear problems aside from hearing impairments also hit a record high at 2.9 percent.

On the other hand, the ratios for tooth decay continued to fall, setting record lows of 34 percent in junior high schoolers and 43.7 percent in high schoolers.

The downtrend is being credited to improved education on brushing teeth at school and greater awareness of parents about dental hygiene.

The survey also found that the proportion of 13-year-olds in Fukushima Prefecture weighing at least 20 percent more than standard stood at 12.29 percent, the highest by prefecture.

While obesity in children rose after the March 2011 nuclear disaster, which caused restrictions to be placed on outdoor activities as a result of contamination, It cannot be said that (the proportion in Fukushima) is markedly higher than in other prefectures, so there may not be any significant effect, the ministry said.

Original post:
In the age of smartphones, Japanese schoolchildren's eyesight is worst on record, health ministry finds - The Japan Times

PEORIA Bryce Weiler has a vision: Help people with disabilities connect with sports.

Weiler was born without eyesight, but he hasn't let that hamper his love for sports. He has worked as a broadcast color commentator for more than 140 games, one of which was a Peoria Chiefs game at Dozer Park in 2014.

He played catch on the field with then-Chiefs manager Joe Kruzel. He can hit a baseball. Shoot free throws. You name it, he's tried it.

And that's what he wants for everyone with a disability. To that end, the Baltimore Orioles disability consultant co-founded the Beautiful Lives Project after his college days.

Beautiful Lives helps sports organizations create participation chances for people with disabilities.

And one of those events happened Saturday during a basketball game at Galva High School.

The Galva dance team welcomed a handful of students with disabilities, led them through practice on Friday, and then danced with them at halftime on Saturday.

"We had three students, two from Geneseo and one from Kewanee, join us for this," Galva dance team coach Ali Weston said. "The goal for us was to be inclusive. I wanted our dancers to experience this, and work toward helping others achieve something they didn't think they could do.

"None of the three guests who joined us had a background in dance. They wanted to experience it and we were excited to help them."

Weston met Weiler when the two were students at Western Illinois University. She danced for WIU and Weiler became a friend.

"We found out we both had a love for sports," said Weston, 26. "The thing you have to know about Bryce is, any obstacle that comes into his path he embraces and overcomes."

The idea for the Galva dance event was formed over the summer.

"I just thought it was an amazing opportunity," Weston said. "It helps our dancers, too. They learn what it is like for someone who cant do all the things that they can do."

Said Galva junior dance team member Jacqueline Boyce:

"This is a good opportunity for our dance team to reach out to people who haven't had the experiences we've had."

Weiler earned a bachelor's degree in Sports Management and Communication from University of Evansville, and earned a master's in Sports Administration from Western Illinois.

He was born with the retinas in his eyes detached, so he's never had sight. But he certainly has vision.

"The Beautiful Lives Project is my chance to give back to all the people who have helped me out," said Weiler, 28. "Ali has been such a good friend, helped me so much at Western Illinois and is such a good person.

"She's passing along these experiences to her dance team now, and that's a great thing."

You can check out the Beautiful Lives Project at https://www.beautifullives.org/.

Dave Eminian covers the Rivermen and Chiefs for the Journal Star, and writes the Cleve In The Eve sports column for pjstar.com. Reach him at 686-3206 or deminian@pjstar.com. Follow him on Twitter @icetimecleve.

Continue reading here:
Cleve In The Eve: Beautiful Lives Project teams up with Galva dance team for special event - Peoria Journal Star

Andy Warhol. All images courtesy of Supple and totalcontent

This is certainly a sight for sore eyes: a printed wall calendar for 2020, inspired by famous spectacle wearers past and present, ranging from Gandhi to Ga Ga, Elton John to Audrey Hepburn.

Brought to you by design studio Supple and copywriting firm totalcontent, 2020 Visionaries focuses on familiar specs and the little-known stories behind them.

Supple went all ocular on the design, basing the creative on graphic illustrations of the iconic face furniture, judicious use of the Optician Sans font, and a take on the traditional opticians' Snellen vision test chart on the cover.

The glasses illustrations are reproduced true to size. The lenses reflect not only the identity of the wearer but what they might see through them. For example, January poster boy Michael Caine's lenses feature a couple of speeding Minis, a nod to his iconic British heist movie The Italian Job.

totalcontents Jim K Davies says: "I had the idea for a spectacles-based calendar a couple of years ago when I saw '2020' printed in a newspaper. The research was a real eye-opener. Most interesting find? Elton John doesn't need specs anymore, thanks to the lens implantsurgery he had in 2003. It was a shame not to include Dame Edna though. Her extravagant glasses dont have lenses, so, unfortunately, we couldnt use her."

Designer and illustrator Yee Poon adds: After Jim suggested a 2020 calendar of famous spec wearers, we explored loads of ways of featuring the glasses, before focusing on the idea of reflections. We decided to keep things pure and simple, taking our cues from eye-test cards for colour, typography and minimalism."

The 2020 Visionaries calendar is supported by a pop-up microsite by web design agency Our Name is Mud, along with a link for donations to Guide Dogs for the Blind, one of Supple's clients.

Creative Director Matt Powell said: "When we saw the calendar, we immediately thought it would lend itself to an online quiz and we could have some fun with opticians' iconography. The red and green screens lend themselves beautifully to right and wrong and using some clever mask effects, we could mimic the way test lenses work."

Michael Caine

Elton John

John Lennon

Amelia Earhart

Ray Charles

Billie Jean King

Lady Gaga

Audrey Hepburn

Gandhi

Karl Lagerfeld

The Two Ronnies

Go here to see the original:
Supple's eye-catching 2020 calendar inspired by famous spectacle wearers and your local opticians - Creative Boom

Las Vegas, NV, Dec. 20, 2019 (GLOBE NEWSWIRE) -- The 27th Annual World Congress concluded on Sunday, December 15th at the Venetian/Palazzo Resort in Las Vegas. As the largest event in Anti-Aging medicine worldwide, the conference hosted thousands of the industrys leading clinical professionals including renowned practitioners, innovative companies, and like-minded partner organizations. The annual conference boasted an extensive agenda featuring five pre-conference workshops, a brand new Aesthetics Symposium, the annual MedTech Impact on Wellness symposium, an extensive variety of session topics, and a faculty panel consisting of the foremost clinical experts and thought leaders in Anti-Aging and Integrative medicine. Rooted in a forward-focused mission to redefine modern medicine, this conference disseminated the most valuable knowledge, recent updates, and clinical expertise within Anti-Aging medicine available.The event began with five pre-conference workshops covering a broad range of topics. Led by industrys experts, pre-conference attendees gained valuable and in-depth knowledge during workshops focused on Precision Medicine and Diabetes, Hormones and Chronic Disease, Peptides and Aging, Stem Cells, and Practice Management. In placing an emphasis on equipping practitioners with the advanced capabilities to improve clinical outcomes and enhance practice efficiency, these pre-conference workshops offered clinicians the opportunity to begin the conference with actionable knowledge ready to be integrated into practice.The congress featured three keynote speakers from a diverse range of clinical backgrounds but each serving, in their own respective right, as a pioneering leader in a new and transformative form of healthcare. On the first day of the conference, attendees heard Dr. Anna Lembke, MD share her keynote presentation titled: The Opioid Epidemic: From Freud to Fentanyl. Currently serving as the program director for the Stanford Addiction Medicine Fellowship, psychiatrist Dr. Lembke, was one of the first in the medical community to sound the alarm regarding the epidemic of over-prescribing opioids. During the second day of the conference, attendees learned from Dr. Robert Pearl MDthe former CEO of Kaiser Permanente and longstanding prominent authority on healthcare culture and delivery. Dr. Pearl provided listeners with valuable and timely insight during his presentation on Fixing American Healthcare: Structure, Reimbursement, and an Aging Population. On the third day of the conference, Dr Louise Aronson, MD took the stage to share her presentation titled Future of Elderhood: Life, Vitality, and Transformation. A Harvard graduate, leading geriatrician, Professor of Medicine at the University of California, San Francisco (UCSF), and the author of the New York Times bestseller Elderhood: Redefining Aging, Transforming Medicine, and Reimagining, Dr.Aronson is a well-respected thought leader and practitioner surrounding geriatric care and the process of aging. In questioning the status quo and pushing well-beyond traditional standards of medicine, these speakers helped lead attendees in envisioning and ultimately practicing a redefined form of medicine. The conferences newest educational offering, The Aesthetics Symposium, provided in-depth understanding surrounding one of the most quickly expanding industries: aesthetic medicine. Hosted in partnership with the South Beach Symposium and led by aesthetic medicine experts Mark S. Nestor, MD, PhD, and Michael H. Gold, MD and anti-aging thought leader, Patrick Bitter, MD, The Aesthetic Symposium provided an in-depth and comprehensive examination of the latest advancements, novel technology, and market knowledge available within modern aesthetic medicine. The conference additionally featured the MedTech Impact on Wellness symposium, an annual educational symposium centered upon the emerging clinical value in digital health. The event hosted digital health stakeholders, clinicians, health IT executives, entrepreneurs, and researchers to promote the development of patient-centered medical technology. Speakers covered a diverse range of topics including application interoperability, telemedicine, the role of artificial intelligence in clinical decision making, and data-driven healthcare among various others.Throughout the entirety of the conference, attendees broke off into afternoon sessions highlighting an extensive variety of topics including targeted approaches to brain and pain, CBD, intermittent fasting, oncological care, gut health and much more. With over 75 educational sessions, 18 learning tracks, 9 Professional Medical Education workshops, and 10 Product Theater presentations, attendees were given the opportunity to customize their conference experience to best suit their clinical needs and interests. The conference additionally provided attendees access to an Exhibit Hall that hosted over 400 companies, showcasing key therapeutic products, devices, and services in Integrative, Anti-Aging, & Aesthetic Medicine: including pharmaceutical products and diagnostic testing, CBD, nutraceuticals and cosmeceuticals, digital health devices, and the most recently available medical technologies. Collectively, the companies offered attendees the opportunity to leave home with valuable resources to integrate into practices across the globe.

Story continues

Sarenka SmithAmerican Academy of Anti-Aging Medicine (A4M)561-997-0112 x7912a.aloi@a4m.com

Excerpt from:
The American Academy of Anti-Aging Medicine Concludes the 27th Annual World Congress - Yahoo Finance

Sons of the Silent Age, a David Bowie tribute band, will be performing "The Rise and Fall of Ziggy Stardust" and "Station to Station" on Saturday, January 11, 2020 at Metro Chicago. Funds raised will benefit integrative medicine therapies for NorthShore University HealthSystem (NorthShore) Kellogg Cancer Center adult and pediatric patients.

An opening set will be performed by The Ready Freddies, playing the music of Queen. Tickets are now on sale at https://foundation.northshore.org/IMConcert. Doors open at 6 p.m. and the show begins at 7 p.m. General admission is $25 in advance; $30 day of; VIP Tickets are $122/each, and include reserved balcony access, an exclusive pre-show party with the artists and a signed poster from the artists. VIP Table Tickets, $222/piece and sold only in pairs, include all VIP benefits, plus a reserved table and seats for two.

Sons of the Silent Age is composed of nine Chicago musicians, when Chris Connelly (Revolting Cocks, Ministry) and Matt Walker (Filter, Smashing Pumpkins and Morrissey's band) joined forces in 2012 to pay tribute to their hero David Bowie.

For the third year, the concert is benefitting the NorthShore Integrative Medicine program, as one of the largest and most-well established programs in the country. Each of the parties involved in the benefit concert from the Sons of the Silent Age bandmates, to the owner of Metro, to the NorthShore Integrative Medicine team share a common bond of commitment to the cause, and for some, cancer survivorship.

"We are again honored to receive proceeds from the fabulous Sons of the Silent Age Benefit Concert at Metro in 2020. Over the past 2 years, concert proceeds and donations have provided free integrative therapies for our patients with limited means to help ease their symptoms from cancer while promoting health and wellness," said Leslie Mendoza Temple, MD, NorthShore Integrative Medicine Medical Director. "We appreciate the dedication of Joe Shanahan, Chris Connolly, Matt and Char Walker, and the band Sons of the Silent Age for their heartfelt contributions to the life and health of our patients."

Integrative medicine programs are designed to relieve pain and neuropathies, reduce fatigue and sleep issues, boost immunity, provide stress relief, improve their appetite and their overall quality of life.

NorthShore cancer patient and stage four cancer survivor, Steve Merola, benefited from the funds raised at last year's benefit concert.

"The integrative medicine services have given me the additional tools and guidance I need to withstand the rigors of chemotherapy and radiation," he explains.

Merola worked with Dr. Mendoza to develop a personalized integrative medicine plan. Through his therapy, Merola noticed the significant impact relaxation had during his fight for recovery. "Thanks to Dr. Mendoza Temple and her team, my stress has been relieved with a program of exercise, meditation, acupuncture, and supplements to help with appetite and stress. With all these services combined I found that I had body, mind, and spirit all aligned to win my fight. It's not over yet, but I am confident I will prevail."

NorthShore's Integrative Medicine Program uses safe, evidence-based complementary therapies and communicating fully with patients' traditional western medicine physicians and specialists optimizes each patient's health and a heightened sense of well-being. Learn more about NorthShore's Integrative Medicine Program or support the cause at foundation.northshore.org/imconcert.

NorthShore University HealthSystem (NorthShore) is an integrated healthcare delivery system consistently ranked as a Top 15 Major Teaching Hospital in the U.S. The NorthShore system, headquartered in Evanston, Illinois, includes four hospitals Evanston, Glenbrook, Highland Park and Skokie. NorthShore also includes a 950+ physician multispecialty group practice, NorthShore Medical Group, with more than 130 practices in the Chicagoland area. NorthShore is a Magnet recognized organization, the first in Illinois to receive this prestigious honor as an entire system that demonstrates nursing excellence and high standards in patient care. The system also includes the NorthShore Research Institute; the NorthShore Foundation; and the NorthShore Home & Hospice Services. As a not-for-profit organization, NorthShore provides $235 million in charitable care and services to the communities it serves, while philanthropic support from individuals and organizations enhances clinical care, research and education programs across the system.

One of the nation's most renowned independent music venues, Metro has hosted thriving local talent and international headliners for 35 years and counting. From industrial champions Ministry and Revolting Cocks to alt-rock pioneers The Smashing Pumpkins and Liz Phair and pop-punk royalty Alkaline Trio and Fall Out Boycountless Chicago artists have laid their roots in Metro as a business, sanctuary, and springboard.

Go here to see the original:
David Bowie Tribute Band at Metro to Benefit NorthShore Patients - Patch.com